Mithradote Bio

Executive Summary

Mithradote Bio is a San Francisco-based biotechnology company founded in 2021 with a focused mission: to develop a self-administered antidote that rapidly reverses the effects of common drink-spiking drugs, thereby preventing drug-facilitated sexual assault. The company's lead product is a novel small-molecule formulation designed for easy, on-the-spot administration, potentially empowering individuals to act quickly in emergency situations. By addressing a critical public safety and healthcare gap, Mithradote Bio aims to significantly reduce the incidence of drug-facilitated assault, which remains a pervasive issue worldwide. The product's mechanism targets multiple common sedatives found in spiked drinks, offering broad-spectrum protection. While the company is still in early preclinical stages, its value proposition is compelling, and its regulatory pathway may be expedited given the public health urgency and potential for compassionate use or orphan drug designation.

Upcoming Catalysts (preview)

• Q4 2026Completion of lead optimization and selection of clinical candidate70% success
• Q3 2027IND-enabling studies and submission of Investigational New Drug application with FDA40% success
• TBDPartnership or funding announcement with public health or defense organizations50% success